KALA BIO — Third Quarter 2026 Earnings Summary

Financial Performance:

• Reported a net loss of approximately $0.8 million for the third quarter of 2026, a reduction of approximately 90% compared to $7.6 million in the same period of 2025.
• Reported a net loss of approximately $4.0 million for the nine months ended September 30, 2026, compared to $27.7 million for the same period in 2025.
• Held cash, cash equivalents, and short-term investments of approximately $7.0 million as of September 30, 2026.
• Maintained a debt-free balance sheet as of September 30, 2026.

Management Commentary and Tone:

• Avi Minkowitz, CEO and CFO, stated the company reduced its quarterly net loss by approximately 90% year-over-year and is continuing to develop initiatives put in motion.
• Management thanked stockholders for attending the Annual Meeting on November 3, 2026, and for their continued support.

Other Key Points:

• The company is a clinical-stage biopharmaceutical firm operating a dual strategy combining a proprietary biologics pipeline (including an MSC-S platform and FDA Orphan Drug- and Fast Track-designated candidates) with a scalable AI platform-as-a-service business.
• KALA BIO holds an exclusive worldwide license for the Researgency AI research platform from Younet to serve as a dedicated AI infrastructure partner for the biotechnology industry.
• The company is advancing an agentic transformation strategy through Researgency.ai, designed to enable scalable, governed deployment of AI agents across research, documentation, and operational workflows.
• Preliminary unaudited results are subject to completion of financial close procedures and review by the independent registered public accounting firm; final results may differ.
• The company expects to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, with the SEC on or about November 16, 2026.